209 related articles for article (PubMed ID: 37081052)
41. Computed tomographic findings of environmental asbestos-related malignant pleural mesothelioma.
Yilmaz UM; Utkaner G; Yalniz E; Kumcuoglu Z
Respirology; 1998 Mar; 3(1):33-8. PubMed ID: 9657657
[TBL] [Abstract][Full Text] [Related]
42. miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
Xu Y; Zheng M; Merritt RE; Shrager JB; Wakelee HA; Kratzke RA; Hoang CD
Chest; 2013 Nov; 144(5):1632-1643. PubMed ID: 23828229
[TBL] [Abstract][Full Text] [Related]
43. Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma.
Ferrari L; Iodice S; Cantone L; Dallari B; Dioni L; Bordini L; Palleschi A; Mensi C; Pesatori AC
Med Lav; 2022 Dec; 113(6):e2022052. PubMed ID: 36475505
[TBL] [Abstract][Full Text] [Related]
44. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
45. Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
Kato K; Gemba K; Fujimoto N; Aoe K; Takeshima Y; Inai K; Kishimoto T
Anticancer Res; 2016 Mar; 36(3):1067-72. PubMed ID: 26976999
[TBL] [Abstract][Full Text] [Related]
46. A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma.
Oliveto S; Alfieri R; Miluzio A; Scagliola A; Secli RS; Gasparini P; Grosso S; Cascione L; Mutti L; Biffo S
Cancer Res; 2018 Oct; 78(20):5741-5753. PubMed ID: 30072395
[TBL] [Abstract][Full Text] [Related]
47. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M
Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844
[TBL] [Abstract][Full Text] [Related]
49. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
50. On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).
Barbieri PG; Mirabelli D; Magnani C; Brollo A
Tumori; 2019 Aug; 105(4):304-311. PubMed ID: 29714657
[TBL] [Abstract][Full Text] [Related]
51. Non-asbestos-related malignant pleural mesothelioma.
Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
[TBL] [Abstract][Full Text] [Related]
52. Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies.
Santarelli L; Gaetani S; Monaco F; Bracci M; Valentino M; Amati M; Rubini C; Sabbatini A; Pasquini E; Zanotta N; Comar M; Neuzil J; Tomasetti M; Bovenzi M
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):119-126. PubMed ID: 30257964
[TBL] [Abstract][Full Text] [Related]
53. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
[TBL] [Abstract][Full Text] [Related]
54. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.
Benjamin H; Lebanony D; Rosenwald S; Cohen L; Gibori H; Barabash N; Ashkenazi K; Goren E; Meiri E; Morgenstern S; Perelman M; Barshack I; Goren Y; Edmonston TB; Chajut A; Aharonov R; Bentwich Z; Rosenfeld N; Cohen D
J Mol Diagn; 2010 Nov; 12(6):771-9. PubMed ID: 20864637
[TBL] [Abstract][Full Text] [Related]
55. Physician requests by patients with malignant pleural mesothelioma in Japan.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
[TBL] [Abstract][Full Text] [Related]
56. Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.
Lee LJ; Lin CK; Pan CH; Cheng Y; Chang YY; Liou SH; Wang JD
BMJ Open; 2018 Dec; 8(12):e021063. PubMed ID: 30530573
[TBL] [Abstract][Full Text] [Related]
57. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
58. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
59. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
Lin RT; Chang YY; Wang JD; Lee LJ
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
[TBL] [Abstract][Full Text] [Related]
60. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
